Ionis Pharmaceuticals Inc. (IONS) and Biogen Inc. (BIIB) announced Monday morning that the Phase 3 study of nusinersen in infantile-onset spinal muscular atrophy met the primary endpoint.
from RTT - Before the Bell http://ift.tt/2arsgVD
via IFTTT
No comments:
Post a Comment